Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Phase I NCT05571839

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors — Active Not Recruiting • Phase I • Oncology • NCT05571839.

📅 07 Apr 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase I
NCT ID
NCT05571839
Start
2023-01-03
Completion
2026-06-06
ClinicaliQ Trial Snapshot
  • A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors — Active Not Recruiting • Phase I • Oncology • NCT05571839.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment
Oncology · 01 May 2025
Use AI technologies as an adjunct to clinical assessment when triaging skin lesions in the urgent suspected cancer pathway, but do not…
View guideline →
Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Guideline
Melanoma: Assessment and Management (NICE NG14)
Oncology · 27 Mar 2026
Excise primary melanomas with 2 cm margins if Breslow thickness ≤2 mm, or 1–2 cm margins if >2 mm, tailored to tumour…
View guideline →
Guideline
Head and Neck Cancers: Diagnosis and Management (NICE NG36)
Oncology · 27 Mar 2026
Refer urgently (two-week wait) any adult with unexplained persistent hoarseness, dysphagia, otalgia, oral ulceration lasting more than 3 weeks, or suspicious neck…
View guideline →
Guideline
EMA Reflection Paper on Extrapolation of Efficacy in Oncology
Oncology · 30 Mar 2026
This EMA guideline addresses EMA Reflection Paper on Extrapolation of Efficacy in Oncology in Oncology. Use it to review current recommendation wording,…
View guideline →
Guideline
Non-Hodgkin’s Lymphoma: Diagnosis and Management (NICE NG52)
Oncology · 27 Mar 2026
Refer urgently via suspected cancer pathway any patient with persistent lymphadenopathy (lymph nodes >1 cm short axis) or splenomegaly without clear infective…
View guideline →